Los Angeles Capital Management LLC Purchases 18,558 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Los Angeles Capital Management LLC increased its holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 9.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 219,997 shares of the company’s stock after buying an additional 18,558 shares during the period. Los Angeles Capital Management LLC’s holdings in RAPT Therapeutics were worth $348,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. JPMorgan Chase & Co. grew its stake in RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after purchasing an additional 25,130 shares during the period. Readystate Asset Management LP bought a new stake in shares of RAPT Therapeutics during the 3rd quarter worth $36,000. Barclays PLC grew its position in RAPT Therapeutics by 277.2% during the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after buying an additional 29,195 shares during the period. SG Americas Securities LLC increased its holdings in RAPT Therapeutics by 401.9% during the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock worth $84,000 after buying an additional 42,636 shares during the last quarter. Finally, Medicxi Ventures Management Jersey Ltd bought a new stake in RAPT Therapeutics in the fourth quarter worth about $35,316,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

RAPT Therapeutics Price Performance

NASDAQ:RAPT opened at $1.05 on Tuesday. RAPT Therapeutics, Inc. has a 1 year low of $0.79 and a 1 year high of $10.05. The stock’s fifty day moving average price is $1.30 and its two-hundred day moving average price is $1.58. The company has a market cap of $36.71 million, a P/E ratio of -0.38 and a beta of 0.03.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Wells Fargo & Company reduced their target price on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday, November 11th. Stifel Nicolaus reissued a “hold” rating and issued a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Piper Sandler cut RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $8.00 to $2.00 in a research report on Monday, November 11th. Finally, HC Wainwright upgraded RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a research note on Thursday, December 26th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.29.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.